These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 37170596

  • 1. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
    Bailey SR, Wyte-Lake T, Lucas JA, Williams S, Cantone RE, Garvey BT, Hallock-Koppelman L, Angier H, Cohen DJ.
    Subst Use Misuse; 2023; 58(9):1143-1151. PubMed ID: 37170596
    [Abstract] [Full Text] [Related]

  • 2. Patients' and Clinicians' Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study.
    Wyte-Lake T, Cohen DJ, Williams S, Casey D, Chan M, Frank B, Levander XA, Stein D, White KK, Bailey SR.
    J Gen Intern Med; 2024 Sep; 39(12):2179-2186. PubMed ID: 38228990
    [Abstract] [Full Text] [Related]

  • 3. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
    Marshall SA, Siebenmorgen LE, Youngen K, Borders T, Zaller N.
    J Prim Care Community Health; 2024 Sep; 15():21501319241246359. PubMed ID: 38600789
    [Abstract] [Full Text] [Related]

  • 4. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
    Frost MC, Zhang L, Kim HM, Lin LA.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2236298. PubMed ID: 36223118
    [Abstract] [Full Text] [Related]

  • 5. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
    Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2252381. PubMed ID: 36692880
    [Abstract] [Full Text] [Related]

  • 6. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA, Sarpong A, Sistad R, Roth C, Banducci AN, Simpson T, Hyde J, Davenport M, Weisberg R.
    J Subst Use Addict Treat; 2024 Jan 03; 156():209188. PubMed ID: 37866437
    [Abstract] [Full Text] [Related]

  • 7. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV, Engel-Rebitzer E, Dolan A, Oyekanmi K, Mandell D, Meisel Z, South E, Lowenstein M.
    Harm Reduct J; 2021 Nov 25; 18(1):119. PubMed ID: 34823538
    [Abstract] [Full Text] [Related]

  • 8. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Psychiatry; 2022 Oct 01; 79(10):981-992. PubMed ID: 36044198
    [Abstract] [Full Text] [Related]

  • 9. How Does Telehealth Expansion Change Access to Healthcare for Patients With Different Types of Substance Use Disorders?
    Tilhou AS, Burns M, Chachlani P, Chen Y, Dague L.
    Subst Use Addctn J; 2024 Jul 01; 45(3):473-485. PubMed ID: 38494728
    [Abstract] [Full Text] [Related]

  • 10. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM, Verrastro G, Fusco CW, Wilson CG, Ostrach B.
    J Rural Health; 2021 Jun 01; 37(3):467-472. PubMed ID: 33720447
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
    Couch JV, Whitcomb M, Buchheit BM, Dorr DA, Malinoski DJ, Korthuis PT, Ono SS, Levander XA.
    Harm Reduct J; 2024 Jun 27; 21(1):125. PubMed ID: 38937779
    [Abstract] [Full Text] [Related]

  • 13. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM, Moore DT, Wischik DL, Lazar CM, Rosen MI.
    J Subst Abuse Treat; 2022 Aug 27; 139():108777. PubMed ID: 35346533
    [Abstract] [Full Text] [Related]

  • 14. Telehealth Utilization for Opioid Use Disorder: A Nationwide Analysis Before and After the COVID-19 Public Health Emergency Declaration.
    Lewis KN, Zhang D, Corrales G, Eswaran H, Hayes CJ, Gressler LE.
    Telemed J E Health; 2024 Jun 27; 30(7):e1980-e1989. PubMed ID: 38621153
    [No Abstract] [Full Text] [Related]

  • 15. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH, Cales SC, Shreffler J, Huecker MR.
    J Subst Abuse Treat; 2022 Feb 27; 133():108543. PubMed ID: 34210567
    [Abstract] [Full Text] [Related]

  • 16. Targeting Patients' Cognitive Load for Telehealth Video Visits Through Student-Delivered Helping Sessions at a United States Federally Qualified Health Center: Equity-Focused, Mixed Methods Pilot Intervention Study.
    Antonio MG, Williamson A, Kameswaran V, Beals A, Ankrah E, Goulet S, Wang Y, Macias G, James-Gist J, Brown LK, Davis S, Pillai S, Buis L, Dillahunt T, Veinot TC.
    J Med Internet Res; 2023 Feb 01; 25():e42586. PubMed ID: 36525332
    [Abstract] [Full Text] [Related]

  • 17. Initiating Opioid Use Disorder Medication via Telemedicine During COVID-19: Implications for Proposed Reforms to the Ryan Haight Act.
    Huskamp HA, Riedel L, Uscher-Pines L, Busch AB, Barnett ML, Raja P, Mehrotra A.
    J Gen Intern Med; 2022 Jan 01; 37(1):162-167. PubMed ID: 34713386
    [Abstract] [Full Text] [Related]

  • 18. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA.
    J Subst Abuse Treat; 2020 Nov 01; 118():108124. PubMed ID: 32893047
    [Abstract] [Full Text] [Related]

  • 19. Examining telehealth use among primary care patients, providers, and clinics during the COVID-19 pandemic.
    Der-Martirosian C, Chu K, Steers WN, Wyte-Lake T, Balut MD, Dobalian A, Heyworth L, Paige NM, Leung L.
    BMC Prim Care; 2022 Jun 18; 23(1):155. PubMed ID: 35717159
    [Abstract] [Full Text] [Related]

  • 20. Telehealth sustains patient engagement in OUD treatment during COVID-19.
    Langabeer JR, Yatsco A, Champagne-Langabeer T.
    J Subst Abuse Treat; 2021 Mar 18; 122():108215. PubMed ID: 33248863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.